Clearside Biomedical Inc (CLSD NASDAQ) stock market data APIs
$0.8073
-0.02(-2.5%)
as of June 30, 2025
Try our APIs with
free plan!
Clearside Biomedical Inc Financial Data Overview
Price chart is built with
Anychart
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Prev. Close
0.8073
Open
0.7844
High
0.8073
Low
0.7844
52 wk Range
0.7001-1.65
Market Cap
59 836 K
Shares Outstanding
77 708 K
Revenue
3 764 K
EPS
-0.11
Beta
2.058
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Clearside Biomedical Inc data using free add-ons & libraries
Get Clearside Biomedical Inc Fundamental Data
Clearside Biomedical Inc Fundamental data includes:
- Net Revenue: 3 764 K
- EBITDA: -25 595 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Clearside Biomedical Inc News
New
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinas...
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase ...
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of thera...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
